Low Float (NBY) Blasts Vertically Up Approximately 85% (Huge Breaking News)

NBY is on fire this morning. Got it on radar? Low Float (NBY) Blasts Vertically Up Approximately 85% (Huge Breaking News) September 11th Dear Reader, NBY is on fire this morning. Got it on radar? If not, you're missing this NYSE American profile exploding up approximately 85% at this moment. After hitting an approximately high of $1.28 in pre-market, NBY needs to be on high alert after breaking news: NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft EMERYVILLE, Calif. & POMPANO BEACH, Fla., September 11, 2023--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and BioStem Technologies, Inc. (OTC: BSEM) announce an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies’ Amniotic Tissue Allograft, which is intended for use as a protective covering during the repair of ocular surfaces. Amniotic Tissue Allograft provides a protective environment or covering for repair of the cornea and conjunctiva, helping ocular surface to return to a healthier state. NovaBay intends to commercialize the prescription-only product as Avenova Allograft to leverage its Avenova eyecare brand and encourage use with other Avenova products. Medically necessary procedures with the Avenova Allograft will be reimbursed through Medicare. Placentally derived human amniotic membrane is a potent source of pro-healing growth factors and anti-inflammatory cytokines. Amniotic allografts have successfully been used in regenerative medicine for over a century and dehydrated human amniotic membrane continues to be widely used as an ophthalmic covering. Avenova Allograft is the only optic allograft manufactured using BioStem Technologies’ patented six-step BioREtain® process that preserves the natural integrity of the placental tissue. This new NovaBay-branded product will compete in the global ophthalmology amniotic membrane market estimated at $403.6Mn in 2022, and is expected to grow at 9.8% per year between 2023-2030. "Avenova Allograft is a differentiated, high-quality product making it an ideal extension of our eyecare franchise," said Justin Hall, CEO and General Counsel of NovaBay. "We look forward to launching Avenova Allograft in the coming weeks and making this valuable solution available for the eyecare professionals who specialize in treating dry eye." ... [Read the full article here.]( With a [low float]( under 4Mn shares and this crazy huge news, NBY needs to be watched closely today. Review my initial NBY report below and get this NYSE American profile front and center quickly. ----- Were you locked in for my latest breakout idea? Alerted for September 7th's opening bell, that Nasdaq profile caught fire early. Running from an open of $.535 to a high of $.6512, my latest champ surged approximately 21% intraday. But let's focus on Monday's opening bell. I've got a doozy of an alert to bring your way. A previous two time champ with 2 strong double-digit short term moves under its belt, including an approximate 94% surge over a few day span right around the new year, this NYSE American profile could turn attention-grabber early this week. One key reason to watch this profile closely is due to its low float status. With fewer than 4Mn shares in its float according to Yahoo Finance, this breakout idea could become a volatile situation if another potential catalyst comes along. Factor in an [analyst target]( suggesting over 1,400% potential upside from Friday's close and a company increasing its international presence in 2023 by tapping into a [Chinese market]( expected to reach $100Bn next year, and you can see why this profile needs immediate attention. Drop everything right now and pull up NYSE American breakout idea: NovaBay Pharmaceuticals, Inc. (NBY). Corporate Overview - The Inner-Workings Of NBY Established Brands in Three Verticals - Avenova - #1 doctor-recommended antimicrobial lid & lash spray in the U.S. dry eye market - DERMAdoctor - more than 30 highly effective, problem-solving dermatological products - PhaseOne and NeutroPhase cutting-edge wound care technology Avenova - Science for sore eyes. - No. 1 Doctor-Recommended Antimicrobial Lid & Lash Spray - Kills a broad spectrum of bacteria and helps relieve chronic eye conditions like dry eye, blepharitis, styes, contact lens discomfort and inflammation - 510(k) FDA-cleared formulation is the only known stable, truly pure HOCI commercial solution - Manufactured and lab tested in the U.S. and clinically proven to be the most effective lid & lash solution available without a prescription - 80-100 times more potent than Clorox bleach yet completely nontoxic Avenova Opp's for Growth DERMAdoctor: A Well-Established Name in the Expanding Skincare Industry Significant Global Growth Opp. - Cosmetic skincare products estimated to reach $185Bn by 2027 - The skincare segment is growing faster than any other part of the beauty industry Grab Source And Key Details Here: [Company Presentation.]( ----- And as mentioned above, NBY has several potential catalysts that could help provide a breakout spark. Check these out: No. 1 NBY Potential Catalyst - Explosive Volatility Potential From Tiny Float According to the [Yahoo Finance]( website, NBY has a tiny low float. The website reports this profile to have approximately 3.93Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. Could positive company news to close out 2023 provide a breakout spark? ----- No. 2 NBY Potential Catalyst - Analyst Targets Could Suggest As Much As 1,400% Potential Upside Edward Woo, an analyst at [Ascendiant Capital Markets]( has tagged NBY with a $9.50 price target. From this past Friday's close, that provides NBY with an incredible upside potential of 1,400+%. [Check out the full report here.]( ----- No. 3 NBY Potential Catalyst - A Massive Prime Day For Avenova-branded Products Breaks Unit Sales And Revenue Daily Records NovaBay Pharmaceuticals Reports Record Avenova Sales Day EMERYVILLE, Calif., July 14, 2023--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that sales of Avenova®-branded products reached a new record during the Amazon Prime Day event held July 11-12, 2023, with sales increasing 22% over Prime Day 2022 and 43% over Prime Day 2021. "Sales of Avenova products during Prime Day 2023 were at an all-time high since we created our direct-to-consumer sales channel in 2019. Unit sales and revenue broke daily records, eclipsing all previous milestones," said Justin Hall, NovaBay CEO. "We are encouraged by this growth in our most important sales channel, and appreciate the loyalty of current Avenova users. We are excited to attract those new to the brand, many of whom we anticipate will become long-term customers." "The results of this year’s Prime Day event further confirms that our marketing strategies are effectively cutting through the clutter of products and advertising, and that our core product, Avenova Antimicrobial Lid and Lash Spray, is used by a broadening and loyal customer base that values its superior efficacy," he added. NovaBay offers a full line of best-in-class Avenova-branded products for the management of chronic dry eye. Its flagship product Avenova Spray is the No. 1 doctor-recommended antimicrobial lid and lash cleanser. Additional Avenova products include lubricating eye drops for instant relief, a warm eye compress to soothe, an antioxidant-rich dietary supplement with omega-3 oils and the i-Chek to monitor physical eyelid health. All Avenova products are highly rated on Amazon.com, with Avenova Spray receiving 4.5 out of 5 stars from nearly 13,000 reviews, including 86% of ratings at 4 stars or above. ... [Read the full article here.]( ----- No. 4 NBY Potential Catalyst - Company's Products Appear On Flagship Shopping Channel "QVC" NovaBay Pharmaceuticals Announces DERMAdoctor’s KP Duty Lotion and Scrub Ultra Duo Set for Dry, Rough, Bumpy Skin to be Featured on QVC ... EMERYVILLE, Calif., June 12, 2023--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Chief Product Officer Dr. Audrey Kunin will appear on QVC®’s Girls Night In with Courtney & Jane on Tuesday, June 13, 2023 at 10:00 p.m. Eastern time to showcase DERMAdoctor®’s system for dry, rough, bumpy skin. ... ... [Read the full article here.]( ----- No. 5 NBY Potential Catalyst - Chinese Order Demonstrates Growing Presence In International Markets NovaBay Pharmaceuticals Fulfills $1Mn Order for NeutroPhase® Skin and Wound Cleanser for China Pioneer Pharma Holdings EMERYVILLE, Calif., May 01, 2023--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces that China Pioneer Pharma Holdings, Limited (HK Stock Code:1345), a leading Chinese importer and marketer of branded pharmaceuticals and medical devices, has placed a $1Mn order for NovaBay’s NeutroPhase Skin and Wound Cleanser. NovaBay has fulfilled this order and expects to recognize this revenue in the second quarter of 2023. "NeutroPhase is the safest, purest and most powerful hypochlorous acid wound cleanser on the market yet is gentle, non-irritating and non-sensitizing to skin and new tissue," said Justin Hall, CEO of NovaBay Pharmaceuticals. "Importantly, NeutroPhase differentiates itself in the marketplace because it does not contain the toxic chemicals found in many other wound care products. We proudly manufacture NeutroPhase in the U.S. in large batch quantities through a proprietary process." "The efficacy of NeutroPhase is unparalleled in the wound care market. We are proud of our long-term partnership with NovaBay and are delighted to make this high-quality product available to our healthcare customers in China," said Paul Li, Chairman of China Pioneer. ... [Read the full article here.]( ----- NBY Recap - The Top Potential Catalysts For This NYSE American Past Champ No. 1 - Explosive Volatility Potential From Tiny Float No. 2 - Analyst Targets Could Suggest As Much As 1,400% Potential Upside No. 3 - A Massive Prime Day For Avenova-branded Products Breaks Unit Sales And Revenue Daily Records No. 4 - Company's Products Appear On Flagship Shopping Channel "QVC" No. 5 - Chinese Order Demonstrates Growing Presence In International Markets ----- Coverage is officially reinitiated on NBY. When time allows, do this: Get NBY on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 6/25/23 and ending on 6/27/23 to publicly disseminate information about (NBY) via Website, Email and SMS. SWN Media LLC was paid seventeen thousand five hundred and one cent USD via bank wire transfer. We own zero shares of (NBY). Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 9/10/23 and ending on 9/11/23 to publicly disseminate information about (NBY) via Website, Email and SMS. SWN Media LLC was paid ten thousand USD via bank wire transfer. We own zero shares of (NBY). To date we have been compensated a total of twenty-seven thousand five hundred and one cent USD via bank wire transfer to disseminate information about (NBY). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and JRZ Capital LLC, TD Media LLC has been hired for a period beginning on 06/06/2023 and ending on 09/12/2023 to publicly disseminate information about (NBY:US) via digital communications. We have been paid two hundred thousand dollars USD. We own zero shares of (NBY:US). [( Fierce | 401 W. Atlantic Ave, Ste R10 Unit #271, Delray Beach, FL 33444 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net